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“STUDIES OF SOME HETEROCYCLIC COMPOUNDS OF 
PHARMACEUTICAL IMPORTANCE” 
 
 
A comprehensive summary of the work incorporated in the thesis with the title  
 
“STUDIES OF SOME HETEROCYCLIC COMPOUNDS OF  
 
PHARMACEUTICAL IMPORTANCE” 
  
 has been described as under. 
 
 
 
 PART-1 : STUDIES ON CHALCONES OF 2-(4-
ACETYLPHENYLAMINO) PYRIDINE-3-
CARBONITRILE. 
 
 
 
 PART-2 : CONVENTIONAL AND MICROWAVE ASSISTED 
SYNTHESIS AND EVALUATION STUDIES ON 
PYRAZOLINES. 
 
 
 PART-3 : CONVENTIONAL AND MICROWAVE ASSISTED 
SYNTHESIS AND EVALUATION STUDIES ON 
PYRIMIDINES. 
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PART-1 : STUDIES ON CHALCONES OF 2-(4-
ACETYLPHENYLAMINO) PYRIDINE-3-CARBONITRILE 
 
Many naturally occurring and synthetic compounds contain cyanopyridine as a 
basic moiety, which posses interesting pharmacological properties, Cyanopyridine and its 
derivative are well known for their versatile biological activities like antimicrobial, 
antitubercular, antifungal, antiviral etc. looking to this multifold property exhibited by 
cyanopyridine, we are studying here the synthesis and antimicrobial activity of some 
cyanopyridine derivative. In the present study, this strategy is used for the synthesis of 
this compounds in the hope that they may possess potent biological activities.  
 
 In the present study 2-chloro-3-cyano pyridine and p-amino acetophenone are 
coupled together in ethanol. HCl to give 2-(4-ACETYLPHENYLAMINO) 
PYRIDINE-3-CARBONITRILE 
 
N N
H
CN COCH3
2-(4-acetylphenylamino)pyridine-3-carbonitrile
 
 
The chalcones are α, β-unsaturated ketones containing the reactive ketoethylenic 
group – CO – CH= CH –. Presence of α, β-unsaturated carbonyl system in chalcone 
makes it biologically active. 
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The solution of 2-(4-Acetylphenylamino)pyridine-3-carbonitrile was treated with 
various aldehydes in presence of 40% NaOH solution to give various chalcones TYPE 
(I). 
 
N N
H
CN
R
O
TYPE (I) R= ARYL  
 
R= C6H5-, 4-Cl-C6H5-, 4-OH-C6H5-, 3-NO2-C6H5-……etc 
 
PART-2 : CONVENTIONAL AND MICROWAVE ASSISTED SYNTHESIS AND 
EVALUATION STUDIES ON PYRAZOLINES. 
 
Pyrazolines have attracted attention of medicinal chemists for both with regard to 
heterocyclic chemistry and the pharmacological activities associated with them. The 
pharmaceutical importance of these compounds lies in the fact that they can be 
effectively utilized as antibacterial, antifungal, antiviral, antiparasitic, antitubercular and 
insecticidal agents. 
  
Section-I Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(4,5-dihydro-5-Aryl-1H-pyrazol-3-yl)phenylamino)pyridine-3-
carbonitrile. 
   
Considerable attention has been focused on the development and synthesis of 
pyrazolines of type (II) for obtaining biologically potent molecules which have been 
prepared by the condensation of chalcones of type (I) with hydrazine hydrate. 
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N N
H
CN
R
TYPE (II) R= ARYL
N NH
 
 
R= C6H5-, 4-Cl-C6H5-, 4-OH-C6H5-, 3-NO2-C6H5-……etc 
  
Section-II Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(1-acetyl-4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
  
The pyrazolines of type (III) have been prepared by the condensation of chalcones 
of type (I) with hydrazine hydrate in acetic acid. 
N N
H
CN
R
TYPE (III) R= ARYL
N N
COCH3
 
 
R= C6H5-, 4-Cl-C6H5-, 4-OH-C6H5-, 3-NO2-C6H5-……etc 
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Section-III Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(1-phenyl-4,5-dihydro-5-Aryl-1-phenylpyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
  
The pyrazolines of type (IV) have been prepared by the condensation of chalcones 
of type (I) with Phenyl hydrazine. 
 
 
N N
H
CN
TYPE (IV) R= ARYL
N
R
N
Ph
 
 
 
R= C6H5-, 4-Cl-C6H5-, 4-OH-C6H5-, 3-NO2-C6H5-……etc 
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PART-3 : CONVENTIONAL AND MICROWAVE ASSISTED SYNTHESIS AND 
EVALUATION STUDIES ON PYRIMIDINES. 
 
Pyrimidine is the most important member of all the diazines as this ring system 
occurs widely in living organisms. Pyrimidine and its derivatives have gained 
prominence bacause of their potential pharmaceutical values. 
 
Section-I Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(1,2-dihydro-6-Aryl-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 Compounds containing pyrimidine ring are widely available in nature. Many thio 
pyrimidine derivatives are reported to possess different therapeutic activities. In view of 
these findings, it was considered worthwhile to synthesize some new Thioxopyrimidine 
to study their therapeutic activities. Thio pyrimidine derivatives of Type (VII) have been 
prepared by the reaction of the chalcones of Type (I) with thiourea. 
N N
H
CN
TYPE (VI) R= ARYL
NHN
R
S
 
 
R= C6H5-, 4-Cl-C6H5-, 4-OH-C6H5-, 3-NO2-C6H5-……etc 
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Section-II Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(1,2-dihydro-2-oxo-6-Arylpyrimidin-4-yl)phenylamino)pyridine-
3-carbonitrile. 
 
Oxopyrimidines and its derivatives represent one of the most active class of 
compounds possessing a wide spectrum of biological activities. 
 
In the past years considerable evidence has been accumulated to demonstrate the 
efficiency of pyrimidinones. Oxopyrimidines of Type (VII) have been prepared by the 
condensation of chalcones of Type (I) with urea. 
 
N N
H
CN
TYPE (VII) R= ARYL
NHN
R
O
 
 
R= C6H5-, 4-Cl-C6H5-, 4-OH-C6H5-, 3-NO2-C6H5-……etc 
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Biological Activity: 
The newly synthesized chemical entities would be screened for various biological 
activities. 
 
Summary: 
A brief summary of the entire work performed in Ph.D. would be conversed herein and 
the future opportunities in the related field of work would also be discussed. 
 
Note: All the synthesized compounds are confirmed using various analytical data 
techniques like Thin layer chromatography (TLC), Infrared (IR), Proton nuclear magnetic 
resonance spectroscopy (1H NMR) and Mass Spectroscopy.  
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INTRODUCTION: 
 
Research in the field of pharmaceutical has its most important task in the 
development of new and better drugs and their successful introduction into clinical 
practice. The word 'drug' is derived from the French word 'drogue' which means a dry 
herb. In general way, a drug may be defined as a substance used in the prevention, 
diagnosis, treatment or cure of disease in man or other animals. The basis of 
understanding in the medicinal chemistry lies in awareness of the relationships between 
the chemistry of a particular compound or group of compounds and their interactions 
with the body, which is known as structure activity relationship, and the mechanism by 
which the compound influences the biological system, which is known as its mode of 
action. 
 
We must always continue to search for drugs which exhibit clear advantages over the 
already existing respective drugs. Such advantages may be: (1) A qualitative or 
quantitative improvement in activity, (2) a partial or total absence of undesirable side 
effects, (3) a lower toxicity, (4) more nutritive value, (5) improved stability and (6) a 
decrease in production cost. 
 
Any drug must ideally have a broad spectrum of activity, with a rapid bactericidal action. 
Some bacteria produce enzymes that can inactivate or modify antibiotics action. Some 
bacteria produce enzymes that can inactivate or modify antibiotics, and insusceptibility of 
a drug to such degradation or modification could result in its playing an important part in 
therapy. Likewise, some bacteria possess an outer membrane that acts as a permeability 
barrier to the entry of some, but not all, antibiotics. Drugs that can readily penetrate this 
barrier might again be expected to be of possible clinical importance. 
 
During the period of 1940 to 1960 a large number of important drugs have been 
introduced and this period is regarded as "Golden Period" of new drug discovery. These 
are some of the specific examples representing new therapeutics. 
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NAME OF DRUGS YEAR USAGES 
 
Sulfa drugs     1933  First antibacterial drug 
Penicillin     1940 Antibiotics 
Chloroquine     1945 Antimalarial 
Methyldopa     1950 Antidiabetic 
Chlorthiazide     1957 Diuretic 
Adrenergic betablockers   1958 Coronary Vasodilatory 
Semi synthetic penicillins   1960 Antibacterial 
Trimethoprim     1965 Antimicrobial 
Disodium chromoglycoate   1967 Antiallergic 
 
During the past decade, the threat of antimicrobial resistance has become increasingly 
real and its global dimensions have been increasingly recognized. Antimicrobial 
resistance is defined as a property of bacteria that confers the capacity to inactivate or 
exclude antibiotics, or a mechanism that blocks the inhibitory or killing effects of 
antibiotics, leading to survival despite exposure to antimicrobials. Some bacteria become 
multi-resistant, i.e., resistant to different groups of antibiotics. Increasing reports of 
outbreaks of antimicrobial resistant bacteria, such as hospital outbreaks of vancomycin 
resistant enterococci, community outbreaks of antimicrobial resistant. Streptococcus 
pneumoniae and human and animal outbreaks of multi-resistant. Salmonella 
Typhimurium definitive type 104, have heightened the concerns of the international 
public - and animal-health communities, medical and veterinary clinicians and the 
general public. Another reason for increased concern is the slowing of research and 
development of new antimicrobials due to the cost and time to develop new drugs as well 
as a focus by pharmaceutical companies on developing products for non-infectious 
disease. 
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AIMS AND OBJECTIVES: 
 
In the pharmaceutical field, there has always been and will continue to be a need for new 
and novel chemical entities with diverse biological activities. 
 
Our efforts are focused on the introduction of chemical diversity in the molecular frame 
work in order to synthesizing pharmacologically interesting compounds of widely 
different composition. 
 
During the course of research work, several entities have been designed, generated and 
characterised using spectral studies. The details are as under. 
 
1) To generate several derivatives like chalcones, pyrazolines, cyanopyridines, 
aminopyrimidines, thiosemicarbazones, cyclohexenones, indazoles, barbitones, 
imidazolinones, thiazolidinones and nitriles bearing furan nucleus. 
2) To check the purity of all compounds using thin layer chromatography. 
3) To characterize these products for structure elucidation using spectroscopic 
techniques like IR, PMR and Mass spectral studies. 
4) To evaluate these new products for better drug potential against different strains 
of bacteria and fungi. 
5) Selected compounds have been sent to "Tuberculosis Antimicrobial Acquisition 
and coordinating facility (TAACF), Southern Research Institute, U.S.A.'' for their 
in vitro antitubercular screening. 
 
Microwave Assisted Organic Synthesis: 
1.1 Introduction 
Synthesis of new chemical entities is major bottleneck in drug discovery. 
Conventional methods for various chemical synthesis is very well documented and 
practiced1. The methods for synthesis (Heating process) of organic compounds has 
continuously modified from the decade. In 1855, Robert Bunsen invented the burner 
which acts as energy source for heating a reaction vessel; this was latter superseded 
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by isomental, oil bath or hot plate, but the drawback of heating, though method 
remains the same. Microwave Assisted Organic Synthesis (MAOS), which has 
developed in recent years, has been considered superior to traditional heating. 
Microwave assisted organic synthesis2 (MAOS) has emerged as a new “lead” in 
organic synthesis. The technique offers simple, clean, fast, efficient, and economic for 
the synthesis of a large number of organic molecules. In the recent year microwave 
assisted organic reaction has emerged as new tool in organic synthesis. Important 
advantage of this technology include highly accelerated rate of the reaction, 
Reduction in reaction time with an improvement in the yield and quality of the 
product. Now day’s technique is considered as an important approach toward green 
chemistry, because this technique is more environmentally friendly. This technology 
is still under-used in the laboratory and has the potential to have a large impact on the 
fields of screening, combinatorial chemistry, medicinal chemistry and drug 
development. Conventional method of organic synthesis usually need longer heating 
time, tedious apparatus setup, which result in higher cost of process and the excessive 
use of solvents/ reagents lead to environmental pollution. This growth of green 
chemistry holds significant potential for a reduction of the by product, a reduction in 
waste production and a lowering of the energy costs. Due to its ability to couple 
directly with the reaction molecule and by passing thermal conductivity leading to a 
rapid rise in the temperature, microwave irradiation has been used to improve many 
organic synthesis. 
 
1.2 Microwave frequency: 
Microwave heating refers the use of electromagnetic waves ranges from 0.01m to 1m 
wave length of certain frequency to generate heat in the material. These microwaves 
lie in the region of the electromagnetic spectrum between millimeter wave and radio 
wave i.e. between I.R and radio wave. They are defined as those waves with 
wavelengths between 0.01metre to 1 meter, corresponding to frequency of 30GHz to 
0.3GHz. 
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1.3 Principle: 
 
The basic principle behind the heating in microwave oven is due to the interaction of 
charged particle of the reaction material with electro magnetic wavelength of 
particular frequency. The phenomena of producing heat by electromagnetic 
irradiation are ether by collision or by conduction, some time by both. All the wave 
energy changes its polarity from positive to negative with each cycle of the wave. 
This cause rapid orientation and reorientation of molecule, which cause heating by 
collision. If the charge particles of material are free to travel through the material (e.g. 
Electron in a sample of carbon), a current will induce which will travel in phase with 
the field. If charge particle are bound within regions of the material, the electric field 
component will cause them to move until opposing force balancing the 
electric force.3-9 
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1.4 Heating Mechanism 
In microwave oven, material may be heated with use of high frequency 
electromagnetic waves. The heating arises from the interaction of electric field 
component of the wave with charge particle in the material. Two basic principal 
mechanisms involve in the heating of material. 
 
1.4.1 Dipolar Polarisation 
Dipolar polarisation is a process by which heat is generated in polar molecules. On 
exposure to an oscillating electromagnetic field of appropriate frequency, polar 
molecules try to follow the field and align themselves in phase with the field. 
However, owing to inter-molecular forces, polar molecules experience inertia and are 
unable to follow the field. This results in the random motion of particles, and this 
random interaction generates heat. Dipolar polarisation can generate heat by either 
one or both the following mechanisms: 
 
1. Interaction between polar solvent molecules such as water, methanol and ethanol. 
2. Interaction between polar solute molecules such as ammonia and formic acid. 
 
The key requirement for dipolar polarization is that the frequency range of the 
oscillating field should be appropriate to enable adequate inter -particle interaction. If 
the frequency range is very high, inter-molecular forces will stop the motion of a 
polar molecule before it tries to follow the field, resulting in inadequate inter-particle 
interaction. On the other hand, if the frequency range is low, the polar molecule gets 
sufficient time to align itself in phase with the field. Hence, no random interaction 
takes place between the adjoining particles. Microwave radiation has the appropriate 
frequency (0.3-30 GHz) to oscillate polar particles and enable enough inter-particle 
interaction. This makes it an ideal choice for heating polar solutions. 
In addition, the energy in a microwave photon (0.037 kcal/mol) is very low, relative 
to the typical energy required to break a molecular bond (80-120 kcal/mol). 
Therefore, microwave excitation of molecules does not affect the structure of an 
organic molecule, and the interaction is purely kinetic. 
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1.4.1. Interfacial Polarization 
 
Interfacial polarization is an effect, which is very difficult to treat in a simple manner, 
and easily viewed as combination of the conduction and dipolar polarization effects. 
This mechanism is important for system where a dielectric material is not 
homogenous, but consists of conducting inclusion of one dielectric in other. 
 
1.4.2. Conduction mechanism 
 
The conduction mechanism generates heat through resistance to an electric current. 
The oscillating electromagnetic field generates an oscillation of electrons or ions in a 
conductor, resulting in an electric current. This current faces internal resistance, 
which heats the conductor. 
The main limitation of this method is that it is not applicable for materials that have 
high conductivity, since such materials reflect most of the energy that falls on them. 
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1.5. Effects of solvents 
 
Every solvent and reagent will absorb microwave energy differently. They each have 
a different degree of polarity within the molecule, and therefore, will be affected 
either more or less by the changing microwave field. A solvent that is more polar, for 
example, will have a stronger dipole to cause more rotational movement in an effort 
to align with the changing field. A compound that is less polar, however, will not be 
as disturbed by the changes of the field and, therefore, will not absorb as much 
microwave energy. Unfortunately, the polarity of the solvent is not the only factor in 
determining the true absorbance of microwave energy, but it does provide a good 
frame of reference. Most organic solvents can be broken into three different 
categories: low, medium, or high absorber, as shown in Figure 6.  
 
The low absorbers are generally hydrocarbons while the high absorbers are more 
polar compounds, such as most alcohols. 
  
Absorbance level Solvents 
High 
DMSO, EtOH, MeOH, Propanols, 
Nitrobenzene, Formic Acid, Ethylene 
Glycol 
Medium 
Water, DMF, NMP, Butanol, 
Acetonitrile, HMPA, Methyl Ethyl 
Ketone, Acetone, Nitromethane, 
Dichlorobenzene, 1,2-Dichloroethane, 
Acetic Acid, trifluoroacetic Acid, 
Low 
Chloroform, DCM, Carbon tetrachloride, 
1,4-Dioxane, Ethy Acetate, Pyridine, 
Triethyamine, Toluene, Benzene, 
Chlorobenzene, Pentane, Nexane and 
other hydrocarbons 
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1.6 Conventional vs. Microwave Heating. 
 
Microwave heating is different from conventional heating in many respects. The 
mechanism behind microwave Synthesis is quite different from conventional 
synthesis. Points enlisted in Table 1, differ the microwave heating from 
conventional heating.10-26 
  
No CONVENTIONAL MICROWAVE 
1 Reaction mixture heating proceeds 
from a surface usually inside surface of 
reaction vessels 
Reaction mixture heating proceeds 
directly inside mixture 
2 The vessel should be in physical 
contact with surface source that is at a 
higher temperature source (e.g. mental, 
oil bath, steam bath etc.) 
No need of physical contact of 
reaction with the higher temperature 
source. While vessel is kept in 
microwave cavities. 
3 By thermal or electric source heating 
take place. 
By electromagnetic wave heating take 
place. 
4 Heating mechanism involve conduction Heating mechanism involve dielectric 
polarization and conduction 
5 Transfer of energy occur from the wall, 
surface of vessel, to the mixture and 
eventually to reacting species 
The core mixture is heated directly 
while surface (vessel wall) is source 
of loss of heat 
6 In conventional heating, the highest 
temperature (for a open vessels) that 
can be achieved is limited by boiling 
point of particular mixture. 
In microwave, the temperature of 
mixture can be raised more than its 
boiling point i.e. superheating take 
place. 
7 In the conventional heating all the 
compound in mixture are heated 
equally. 
In microwave, specific component 
can be heated specifically. 
8 Heating rate is less Heating rate is several fold high 
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1.7 Application of microwave in organic synthesis. 
Following reactions have been performed through microwave heating. 
Sr 
No 
Reaction Ref No Sr No Reaction Ref No 
1 Acetylation reaction 27 18 Diel’s-Alder reaction 44 
2 Addition reaction 28 19 Dimerization reaction 45 
3 Alkylation reaction 29 20 Elimination reaction 28 
4 Alkynes metathesis 30 21 Estrification reaction 46 
5 Allylation reaction 31 22 Enantioselective reaction 47 
6 Amination reaction 32 23 Halogenation reaction 48 
7 Aromatic nucleophillic 
substitution reaction 
33 24 Hydrolysis reaction 49 
8 Arylation reaction 34 25 Mannich reaction 50 
9 Carbonylation reaction 35 26 Oxidation reaction 51 
10 Combinatorial reaction 36 27 Phosphorylation synthesis 52 
11 Condensation reaction 37 28 Polymerization reaction 53 
12 Coupling reaction 38 29 Rearrangement reaction 54 
13 Cyanation reaction 39 30 Reduction reaction 55 
14 Cyclization reaction 40 31 Ring closing synthesis 56 
15 Cyclo-addition 
reaction 
41 32 Solvent free reaction 57 
16 Deacetylation reaction 42 33 Transestrification reaction 46 
17 Dehalogenation 
reaction 
43 34 Transformation reaction 58 
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Part-I 
Studies On Chalcones 
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INTRODUCTION 
 
Heterocycles are abundant in nature and are of great significance to life because 
their structural subunits exist in many natural products such as vitamins, hormones, 
antibiotics etc[1]. Hence, they have attracted considerable attention in the design of 
biologically active molecules [2]. A practical method for the synthesis of such compounds 
is of great interest in synthetic organic chemistry.  
The chemistry of chalcones generated intensive scientific studies throughout the 
world, especially interesting for their biological and industrial applications. Chalcones are 
colored compounds because of the presence of the chromophore and auxochromes. They 
are known as benzalacetophenones or benzylidene acetophenones. Kostanecki and 
Tambor gave the name Chalcone. The alternative names given to chalcones are phenyl 
styryl ketones, b-phenyl acrylphenone, g-oxo-a,g-diphenyl-apropylene and a-phenyl-b-
benzoethylene. 
The chalcones are α, β-unsaturated ketones containing the reactive ketoethylenic 
group – CO – CH= CH –. Presence of α, β-unsaturated carbonyl system in chalcone 
makes it biologically active. Some substituted chalcones and their derivatives have been 
reported to possess some interesting biological properties such as antibacterial, 
antifungal[3], insecticidal[4], anaesthetic[5], analgesic, ulcerogenic[6] etc. Chalcones, 
considered as the precursor of flavonoids and isoflavonoids, are abundant in edible plants 
[7], and have also been shown to display a diverse array of pharmacological activities, 
such as anti-protozoal [8], anti-inflammatory [9], anticancer [10] and antihyperglycemic 
properties [11]. Consequently, the chalcone backbone could be a versatile scaffold for drug 
design. A survey of the literature revealed that some natural [12,13] and synthetic chalcones 
[14] showed significant ALR2 inhibitory activities, and this prompted us to investigate 
potential ARIs derived from chalcone-based compounds. Thus, we focused on the 
compounds having a carboxylic acid moiety that was incorporated into the chalcone 
backbone and synthesized these compounds. 
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SYNTHETIC ASPECT 
A considerable variety of methods are available in literature for the synthesis of 
chalcones. The most convenient method is the one, that involves the Claisen-Schimidt 
condensation of equimolar quantities of an aryl methyl ketones with arylaldehyde in 
presence of alcoholic alkali[15]. 
 
Chalcones possess conjugated double bonds and a completely delocalized Π-
electron system on both benzene rings. Molecules possessing such system have relatively 
low redox potentials and have a greater probability of undergoing electron transfer 
reactions.  Chalcones are synthesized by claisen-schmidt condensation of aldehyde and 
ketone by base catalyzed or acid catalyzed followed by dehydration to yield chalcones. 
 
MECHANISM 
The following mechanism has been suggested for the synthesis of chalcones. 
CH3
O
Ar
OH-
CH2-
O
Ar
H2O
Ar'
O
H CH2-
O
Ar Ar'
O-
H
O
Ar
H2OH+
Ar'
OH
H
O
ArAr'
H
O
ArH2O
(i)
(ii)
+
+
+
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REACTIVITY OF CHALCONES 
The chalcones have been found to be useful for the synthesis of variety of 
Heterocyclic compounds are as under. 
(1) Pyrazolines[16] and their derivatives can be prepared by the condensation of 
chalcones with hydrazine hydrate. 
(2) Chalcones on reaction with semicarbazide hydrochloride in ethanol affords 1-
carboxamide pyrazolines[17]. 
(3) Chalcones on condensation with malononitrile and ammonium acetate yields 2-
amino-3-cyanopyridines[18]. 
(4) Chalcones on reaction with thiourea in presence of alkali/acid yields 2-
thiopyrimidines[19]. 
(5) Chalcones on treatment with guanidine hydrochloride in presence of alkali affords 
2-aminopyrimidines[20]. 
(6) Cyanopyridone[21] derivatives can be prepared by the condensation of chalcone 
with ethyl cyanoacetate. 
(7) Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords 
pyridopyrimidines[22]. 
(8) Isoxazoles[23] can be prepared by the reaction of chalcones with hydroxylamine 
hydrochloride and sodium acetate. 
(9) Chalcones on treatment with urea in presence of alkali affords 2-oxo 
pyrimidines[24]. 
(10)  Chalcones react with monoethanolamine in ethanol gives 1,4-oxazipines[25]. 
(11) Oxirane[26] can be prepared by the reaction of chalcone with H2O2 in basic media. 
(12) Chalcones on reaction with barbituric acid gave barbitone[27] derivatives. 
(13) Chalcone gives imine derivatives with amine in presence of sulfuric acid as 
catalyst[28]. 
(14) Chalcones on condensation with malononitrile in pyridine forms 2-amino-3-
cyanopyrans[29]. 
(15) Chalcones react with P2S5 yielded 2-isothiazolidines[30]. 
(16) Chalcones react with sodium nitrile in presence of glacial acetic acid in ethanol 
produces 2-1H-pyrimidines[31]. 
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(17) Chalcones with 2-amino thiophenol in acetic acid produces 1,5-thiazepines[32]. 
 
THERAPEUTIC IMPORTANCE 
Chalcone derivatives have been found to possess wide range of therapeutic 
activities as shown below. 
1. Antiallergic[33] 
2. Antiinflammatory[34,35] 
3. Antiviral[36] 
4. Anti HIV[37] 
5. Carboxygenase inhibitor[38] 
6. Antitumor[39,40] 
7. Antimalarial[41] 
8. Anticancer[42] 
9. Antileishmanial[43] 
10. Insecticidal[44,45] 
11. Antiulcer[46] 
12. Bactericidal[47,48] 
13. Fungicidal[49-50] 
13. Anthelmintics[51] 
  
Mudalir and Joshi[52]reported insecticidal activity of some phenoxy chalcones. Ko 
et al[53]. have prepared some new chalcones for potent inhibition of platelet aggregation. 
Ziegler et al[54]. reported some chalcones as antiparasitic. The antimalarial activities of 
chalcones have also been reported by Xue et al[55]. and Dominguez et al[56]. Seo et al[57]. 
have synthesized chalcones derivatives and reported them as a-glucosidase inhibitors. 
Larsen and co-worker[58] and Wu et al[59]. have reported anti-plasmodial activity and 
Boeck and et al[60]. have reported anti leishmanial activity of some chalcones. Analogs 
containing nitro, fluorine or bromine group respectively displayed increased selectivity 
against the parasites as compared with natural chalcone. 
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Shao-Jie Wang et al.[61] have synthesized chalcones derivatives (I) and reported 
them as a Aldose Reductase Inhibitors. 
 
R1
O
COOH
R2
R3
R1=CH3, OCH3       R3=H,CH3,OCH3,F,Cl
                      R2=H,OH,CH3
(I)
 
 
Recently Ni Liming et al.[62] have synthesized chalcones and screened for their 
antiinflammatory and cardiovascular activity. Kumar Srinivas et al.[63]have synthesized 
chalcones as a antitumor agent. Ko Horng-Huey et al.[64] have prepared chalcones as 
antiinflammatory agent. Nakahara Kazuhiko et al.[65] have synthesized chalcones and 
tested as carcinogen inhibitors. Antitubercular agents of chalcone derivatives have been 
prepared by Lin Yuh-Meei et al.[66] 
 
A. Nagaraj and C. Sanjeeva Reddy[67] reported Antimicrobial, Antifungal Activity 
of some bis-chalcones (II).  
 
R R
O
HO OH
O
R = H, 4-OCH3, 4-Cl, 2-Cl,4-NO2, 4-Br
(II)
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Furthermore, Alcaraz M. J. et al.[68] have described the role of nuclear factor-
kappa B and heme oxygenase-1 in the action of an anti-inflammatory Chalcone derivative 
in RAW 264.7 cells. Nerya O. et al.[69] have prepared some new chalcones as potent 
tyrosinase inhibitors (III).  
 
O
OMe
OMe
OH
O
(III)
 
 
Dong Hwan Shon et al.[70] have synthesized and investigated the anti-
inflammatory activity of 2,4,6-tris(methoxymethoxy)chalcone derivatives. Liu Mei et 
al.[71] have prepared chalcones and screened for antimalarial activity. Opletalova 
Veronika et al.[72] have synthesized chalcones and tested as cardiovascular agents. 
Moreover, it has been found that chalcone derivatives possesses nitric oxide 
inhibitor[73,74] anti HIV[75,76]and antiproliferative[77,78] activities. 
 
Moreover, Khatib S. et al.[79] synthesized some novel chalcones as potent 
tyrosinase inhibitors (IV). Ko H. H. et al.[80] have prepared some new chalcones for 
potent inhibition of platelet aggregation. Ziegler H. L. et al.[81] reported chalcones as an 
antiparasitic. Go M. L. et al.[82] have described the synthesis and biological activities of 
chalcones as antiplasmodial. A new class of sulfonamide chalcones (V) synthesized and 
their glycosidase inhibitory activity[83] were investigated. 
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OH
HO
O
OH
OH
(IV)
 
 
O
S
O
O
H
NCH3 R
(V)R = 3 OR 3,4-OH
 
 
N. Lall and co-workers[84] have synthesized 2’,4’,6’-trihydroxy-3’- 
phenylchalcone and 4’,6’,5”-trihydroxy-6”,6”-dimethyldihydropyrano[2”,3”-2’,3’] 
chalcone as an antiviral and antitubercular agents. M. L. Ferrnandiz et al.[85] have 
synthesized phenylsulphonylurenyl chalcone derivatives with various patterns of 
substitution and tested for their effect on nitric oxide (NO) and prostaglandin 
E2(PGE2)overproduction in RAW 264.7 macrophages. Several derivatives selectively 
inhibited cyclo-oxygenase-2 (COX-2) activity in human monocytes. C. C. Lin et 
al.[86]have examined 1,3-diphenyl-2-propenone for its effect on proliferation in human 
breast cancer cell lines, MCF-7 and MDA-MB-321. 
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Shah Alam Khan et al.[87] have synthesized some new chalcones containing 1, 4 - 
dioxane ring system (VI) and reported antihepatotoxic activity. 
R2
R3
R1
O
O
O
X
(VI)
 
 
Das B. P. et al.[88] have found that chalcones possesses larvicidal properties. Kim 
Min-Young et al.[89] have synthesized chalcones and tested for their matrix 
metalloproteinase inhibitor activity. Satyanarayana M. et al.[90] have synthesized chalcone 
derivatives as antihyperglycemic activity (VII). 
 
 
O
O
OH
N
H3C
CH3
R
(VII)
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Prem P. Yadav and co-workers[91] have synthesized nitrogen and sulfur containing 
furanoflavonoids and thiophenylflavonoids (VIII), which have been screened for 
antifungal and antibacterial activity. Meng C. Q. et al.[92] discovered some novel hetero 
aryl substituted chalcones as inhibitors of TNF-alpha-induced VCAM-1 expression (IX). 
 
 
X OH
O
R
X = NCH3/S
R = H/OCH3
(VIII)
 
 
 
 
H3CO
H3CO
OCH3
O OCH3
OCH3
S
(IX)
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Simon F. Nielsen et. al.[93]have been describes how the introduction of “cationic” 
aliphatic amino groups in the Chalcone scaffold results in potent antibacterial compounds        
morever Leroy Krbechek et. al.[94]  describes three new, sweet dihydrochalcones and 
related compounds (XI, XII), One of these, 2’,4’,6‘,3 - tetrahydroxy - 4 - n - 
propoxydihydro-chalcone 4‘-/3-neohesperidoside, was found to be preapproximately 
2000 times sweeter than sucrose on a weight basis. 
 
 
 
HO
O O
OH
(X)
 
 
 
OHRO
OH
C
O
CH2
H2C
X
Y
OHRO
OH
C
O
CH
HC
X
Y
(XI) (XII)
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Chalcones have been proved to be an important intermediate for the synthesis of 
many heterocyclic compounds in organic chemistry. These facts prompted us to 
synthesize some new chalcone derivatives in order to achieving better therapeutic agents 
described as under.  
 
With the biodynamic activities of chalcones and it is a good synthon for various 
heterocyclic rings, the interest has been focused on the synthesis of new chalcones. With 
a view to obtained compounds having better therapeutic activity, we have synthesized 2-
(4-Acetylphenylamino) pyridine-3-carbonitrile with various aromatic aldehydes in 
presence of catalytic amount of alkali. 
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Part - 1 
 
STUDIES ON Chalcones OF 2-(4-Acetylphenylamino) pyridine-3-
carbonitrile 
 
With the biodynamic activities of chalcones and it is a good synthon for various 
heterocyclic rings, the interest has been focused on the synthesis of new chalcones. With 
a view to obtained compounds having better therapeutic activity, we have synthesized 
chalcones of 2-(4-Acetylphenylamino) pyridine-3-carbonitrile with various aromatic and 
aliphatic aldehydes. 
 
N N
H
CN
R
O
TYPE (I) R= ARYL  
 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy.  
 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A.niger and C.albicans at a concentration of 40μg/ml. The 
biological activities of synthesized compounds were compared with standard drugs. 
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N N
H
CN
R
O
N N
H
CN COCH3
RCHO
40% KOH
N Cl
CN
H2N
COCH3
2-3 Drops con HCl
EtOH
TYPE (I) R= Aryl
Reaction Scheme 
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IR Spectral study of 2-(4-(3-(4-methoxyphenyl)acryloyl) 
phenylamino)pyridine-3-carbonitrile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type Vibration Mode Frequency 
cm-1 
References 
Alkane 
 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.)  
2808 
2760 
1498 
1342 
95 
,, 
,, 
,, 
Aromatic C-H str. 
C=C  
 
3101 
1525 
95 
,, 
Azomethane N=C str.  
C-N str.  
 
1593 
1280 
96 
,, 
Nitrile N-H str. (sym.) 
C=N str. 
3367 
2222 
96 
,, 
N N
H
O
CN
OCH3
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1H NMR spectral study of 2-(4-(3-(4-methoxyphenyl)acryloyl) 
phenylamino)pyridine-3-carbonitrile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signal No Signal Position 
δppm 
Relative No 
Of Protons 
Multiplicity Inference 
1 3.8 3H Singlet -OCH3 (f) 
2 6.7 2H Doublet -CH (h, h’) 
3 7.9-7.7 2H double doublet Vin (a-b) 
4 8.2 1H Singlet (broad) -NH (e) 
5 8.4 1H Doublet -CH (k) 
N
CN
N
H
OCH3
O
a
b c
c'
d
d'
e
f
g
g'
h
h'
i
j
k
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Mass spectral study of 2-(4-(3-(4-methoxyphenyl)acryloyl) 
phenylamino)pyridine-3-carbonitrile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
NH
O
NC
OCH3
C
22
H
17
N
3O
2
M
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. W
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EXPERIMENTAL 
 
Synthesis of chalcones of 2-(4-ACETYLPHENYLAMINO) PYRIDINE-3-
CARBONITRILE 
 
(A)  Preparation of 2-(4-acetylphenylamino)pyridine-3-carbonitrile. 
A Mixture of 2-chloro-3-cyanopyridine (0.01 M), p-aminoacetophenone (0.01 M) 
and few drops of Con HCl, taken in RBF with 20 ml Ethanol and was refluxed for 
16 hours on water bath. Contain was allowed to cool at room temperature for 30 
minutes, the separated solid was collected and washed with cold ethanol, 
crystallized from hot ethanol. Yield 80%, m.p. 163°C. (C14H13N3O; required: C 
70.87%, H 4.46%, N 17.71%, found: C 70.63%, H 4.31%, N 17.65%). 
 
(B)  Preparation of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile. 
A Solution of Benzaldehyde (0.01 M) in minimum quantity of DMF (5 ml) was 
added to the mixture of 2-(4-acetylphenylamino)pyridine-3-carbonitrile in 15ml 
DMF and 40% KOH was added to make mixture alkaline, the reaction mixture 
was then stirred for 24 hours at room temperature. The product was isolated by 
adding mixture in cold water and crystallized it from DMF. Yield 77%, m.p. 
254°C. (C21H15N3O; required: C 77.52%, H 4.65%, N 12.91%; found: C 77.39%, 
H 4.53%, N 12.86%). 
 
Similarly other substituted chalcones were prepared. The physical constants are 
recorded in Table No. 1. 
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(C) Biological evaluation of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-
carbonitrile 
 
All the products have been evaluated for Antimicrobial activity as describe under. 
 
(I) Antibacterial activity. 
The purified products were screened for their antibacterial activity. The nutrient 
agar broth prepared by the usual method, was inoculated aseptically with 0.5 ml of 24 
hrs. old subcultures of B. subtilis, S. aureus, E. coli and P. aeruginosa in separate conical 
flasks at 40-50oC and mixed well by gently shaking. About 25 ml content of the flasks 
were poured and evenly spreaded in a petridish (13 cm in diameter) and allowed to set for 
two hrs. The cups (10 mm in diameter) were formed by the help of borer in agar medium 
and filled with 0.04 ml (40 μg) solution of sample in DMF. The plates were incubated at 
37OC for 24 hrs and the inhibition of the bacterial growth were measured in millimetre 
and recorded as shown in Table No. 2. 
     
 (II)  Antifungal activity 
A. niger and C. albicans was employed for testing antifungal activity using cup-
plate method. The culture was maintained on Sabouraud's agar slants. Sterilised 
Sabouraud's agar medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal 
spores in a separate flask. About 25 ml of the inoculated medium was evenly spreaded in 
a petridish and allowed to set for two hrs. The cups (10 mm 34 in diameter) were 
punched. The plates were incubated at 30°C for 48 hrs. After the completion of 
incubation period, the zone of inhibition of growth in the form of diameter in mm was 
measured. Along the test solution in each petridish one cup was filled up with solvent 
which acts as control. The zones of inhibition are recorded in Table No. 2.    
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Table No. 1: Physical Data of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-
carbonitrile. 
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Table No. 2: Biological Evaluation Of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-
3-carbonitrile. 
 
Compounds R= Aryl Antibacterial Activity Antifungal Activity 
    B. 
subtilis s. aureus 
P. 
aeruginosa E. coli A. niger 
C. 
albicans 
1a 3-NO2-C6H4- 
19 17 16 13 
11 9 
1b 4-Cl-C6H4- 14 13 18 19 13 10 
1c C4H3O- 13 16 10 13 7 6 
1d C6H5- 8 10 9 5 3 0 
1e N,N-(CH3)2-C6H4- 
19 11 10 14 
9 8 
1f 4-OCH3-C6H4- 
18 15 14 14 
5 2 
1g 2-OH- C6H4- 
21 18 16 20 
4 4 
1h 2-Cl- C6H4- 15 14 12 15 9 8 
1i 4-OCH3-2-OH-C6H4- 
12 11 14 9 
5 6 
1j 4-OH- C6H4- 
11 9 15 11 
3 5 
1k 
3,4-
(OCH3)2-
C6H4- 18 14 14 12 7 8 
1l 2-OH-C10H6 10 13 8 9 5 3 
1m C8H6N- 7 9 5 8 9 11 
1n C7H14- 12 9 14 10 8 5 
1o 
2,5-
(OCH3)2-
C6H4- 12 15 11 13 7 7 
1p 3,5-Cl2-2-OH-C6H4- 20 17 15 18 14 11 
Sparfloxacin   25 24 25 22 - - 
Benzy 
penicillin   17 18 16 16 - - 
Sparfloxacin   19 23 20 20 - - 
Fluconazole   - - - - 22 20 
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ANTIBACTERIAL ACTIVITY:  
 
From screening results, substituted schiff base 1b (R = -4-Cl-C6H4-) possesses  
very good against E. coli compared with Benzyl penicillin while 1e (R = - N,N-(CH3)2-
C6H4-) and 1g (R= -2-OH- C6H4-) against B. subtilis, 1a (R= -3-NO2-C6H4-) and 1p (R= -
3,5-Cl2-2-OH-C6H4-) against E-coli and B. subtilis possesses moderate activity compared 
with standard. The remaining chalcones possess modrate to poor activity against all four 
bacterial species.  
 
 
ANTIFUNGAL ACTIVITY:  
 
Antifungal screening data showed that substituted chalcones 1p (R = -3,5-Cl2-2-
OH-C6H4-) and 1b (R= -4-Cl-C6H4-) against A. niger show promising activity compare 
with standard drug while 1m (R = - C8H6N-) and 1p (R= 3,5-Cl2-2-OH-C6H4-) , against 
C. albicans shows good activity compare with standard drug. The remaining compounds 
exhibited only moderate to poor activity. 
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Studies On 
 
Pyrazoline Derivatives 
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INTRODUCTION 
Pyrazolines are well known and important nitrogen containing 5-membered heterocyclic 
compounds and various methods have been worked out for their synthesis. Numerous 
pyrazoline derivatives have been found to possess considerable biological activities, 
which stimulated the research activity in this field. They have several prominent effects, 
such as antimicrobial, antimycobacterial, antifungal, antiamoebic, anti-inflammatory, 
analgesic, antidepressant and anticancer activities. They also possess some potent 
receptor selective biological activity like Nitric oxide synthase (NOS) inhibitor and 
Cannabinoid CB1 receptor antagonists activity. 4,5-dihydro-1H- pyrazolines seem to be 
the most frequently studied pyrazoline type compounds. 
 
N
H
N
 
 
As a result, a large number of such pyrazolines using different synthetic methods for their 
preparation have been described in the chemistry literature. The present review provides 
an insight view to pyrazolines synthesis and its biological activities.  
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SYNTHETIC ASPECTS 
Different methods for the preparation of 2-pyrazoline derivatives documented in 
literature are as follows. 
 
N
N
R R1
O
R2NHNH2
R2
R1
R
 
1. The most common procedure for the synthesis of 2-pyrazolines is thereaction of an 
aliphatic or aromatic hydrazine with α,β-unsaturated carbonyl compounds. 
2. Epoxidation of chalcones gave epoxy ketones which reacted with hydrazine and 
phenyl hydrazine to give pyrazolines1. 
3. A number of diarylidene cycloalkanones on reaction with hydrazine hydrate produce 
pyrazolines2. 
4. Dipolar cyclo addition of nitrilimines to dimethyl fumarate, fumaro nitrile and the N-
aryl maleimides yields the corresponding pyrazolines3. 
5. Reaction of Et 2-(phenylazo)-3-oxobutanoates with nicotinic acid hydrazide using 
glacial acetic acid gives following type of pyrazoline derivatives4. 
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REACTION MECHANISM 
The following mechanism seems to be operable for the condensation of chalcones with 
hydraz
 
 
 
 
Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturayed carbonyl system 
forms species (II), in which the -ve charge is mainly accommodated by the electro 
negative oxygen atom. Proton transfer from the nitrogen to –ve oxygen produces an 
intermediate enol which simultaneously ketonises to ketoamine (III). Another 
intermolecular nucleophilic attack by the primary amino group of ketoamine on its 
carbonyl carbon followed by proton transfer from nitrogen to oxygen leads ultimately to 
carbonyl amine (IV). The later with a hydroxy group and amino group on the same 
carbon lose water easily to yield the pyrazolines. 
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THERAPEUTIC EVALUATION 
From the literature survey, it was revealed that 2-pyrazoline derivatives are better 
therapeutic agents. 
1. Diuretic6 
2. Anticonvulsant7 
3. Herbicidal8 
4. Bactericidal9 
5. Antiallergic10 
6. Insecticidal11 
7. Antiimplantation12 
8. Analgesic13 
9. Antitumor14 
10. Antiinflammatory15 
11. Leukotriene inhibitor16 
12. Fungicidal17 
N. Richard18 investigated pyrazolines bis phosphonate ester as novel antiinflammatory 
and antiarthritic agent. Some new 1,3,5-substituted-2- pyrazolines (VI) have been 
described for their antimicrobial activity.19 
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T. Atif and co-workers20 have patented 3-methyl-4'-(substituted phenylazo)- pyrazol-5-
ones as antibacterial agents. R. H. Udupi and A. R. Bhat21 have reported the synthesis and 
biological activity of Mannich bases of certain 1,2- pyrazolines. Pyrazoline derivatives of 
salicylic acid possessing antimicrobial properties have been reported22. T. M. Stavenson 
et al.23 have investigated N-substituted pyrazoline type insecticides. T. Katsuhori24 have 
patented pyrazoline derivatives as herbicides. Pyrazolines derivatives showing significant 
antibacterial activity are described25.  
 
CONTRIBUTION FROM OUR LABORATORY 
Several pyrazolines bearing thymol moiety were evaluated for their ability as potent 
antimicrobial by K. P. Roda.26 Jatin Upadhyay et al.27 have described the pyrazoline 
derivatives and their use as antimicrobial agents. H. J. Vikani and co-workers28 have 
prepared pyrazoline derivatives from arsanilic acid for their antimicrobial activity. Parekh 
et al.29 have synthesised and reported the 
antimicrobial activity of pyrazoline derivatives. Parekh et al.30 have prepared 1-acetyl-5-
aryl-3-[3-(3,4-dihydro-2-methyl- 4-one-3-quinazolinyl)-phenyl]-2-pyrazolines which 
possess antimicrobial activity. 
Akhil Bhatt and co-workers31 have reported pyrazoline derivatives showing antimicrobial 
activity. Parekh et al.32 have synthesised acetyl pyrazoline derivatives bearing quinoline 
moiety (VII) and described their antimicrobial activity. 
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Moreover, some pyrazoline derivatives have been studied for their antidepressant 
activity33. Eggenweiler and co-workers34 have reported some pyrazoline derivatives as 
inhibitors of cGMP and cAMP phosphodiesterase. Pyrazoline derivatives of anthranilic 
acid (VIII) as potent antiinflammatory agents have been investigated35. Maurer et al.36 
have prepared pyrazolines and reported their pesticidal activity. K. Mogilaiah and 
Sudhakar37 have prepared 1,8-naphthyridinyl-2-pyrazolines and studied their antibacterial 
activity. 
 
 
Looking to the diversified activities exhibited and in continuation of our work on the 
synthesis of biologically active compounds, the synthesis and biological screening of 
pyrazoline derivatives have been described as under. 
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Section-I Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 
Section-II Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(1-acetyl-4,5-dihydro-5-Aryl-1H-pyrazol-
3-yl)phenylamino)pyridine-3-carbonitrile. 
 
 
Section-III Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(1-phenyl-4,5-dihydro-5-Aryl-1-
phenylpyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
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Section-I 
Conventional and Microwave assisted Synthesis, biological evaluation of 2-(4-(4,5-
dihydro-5-Aryl-1H-pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
 
Considerable attention has been focused on the development and synthesis of pyrazolines 
of type (II) for obtaining biologically potent molecules which have been prepared by the 
condensation of chalcones of type (I) with hydrazine hydrate. 
 
N N
H
CN
R
N NH
N N
H
CN
R
O
NH2NH2
EtOH
R= ArylType II
 
 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger and C. Albicans. The biological activities of 
synthesized compounds were compared with standard drugs. 
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IR Spectral Study of 2-(4-(4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type Vibration Mode Frequency cm-1 Referance 
Alkane -C-H Str (asym) 
-C-H Str (sym) 
-C-H def. (asym.) 
-C-H def. (sym.) 
 
2958 
2870 
1417 
1336 
38 
,, 
,, 
,, 
Aromatic -C-H str 
-C=C  
-C-H o.o.p. def. 
 
3103 
1550 
831 
,, 
,, 
,, 
Pyrazoline C=N str  
C–N str  
 
1519 
1253 
,, 
,, 
Amine N-H str  3302 39 
Nitrile -C≡N 2353 ,, 
 
N N
H
CN
N NH
OCH3
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1H NMR Spectral Study Of 2-(4-(4,5-dihydro-5-Phenyl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signal 
No 
Signal Position δppm Relative No Of 
Protons 
Multiplicity Inference 
1 2.3 1H Triplet -CHx 
2 2.5-2.6 2H Double doublet -CH2 (Ha. Hb) 
3 6.8 2H Doublet -Ar CH (g, g’) 
4 6.9-7.2 4H Multiplate 
(overlap) 
-Ar CH  
(c, c’, e, j) 
5 7.4 1H Singlet (broad) -NH(y) 
6 8.2 1H Singlet -NH(h) 
N
CN
N
H
N NH
Ha, Hb
x c
d
c'
d'
e
f
f'
g'
g
hi
j
k
y
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Mass Spectral Study of 2-(4-(4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
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EXPERIMENTAL 
Conventional and Microwave assisted Synthesis, biological evaluation of 2-(4-(4,5-
dihydro-5-Aryl-1H-pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
 
[A] Synthesis of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile.   
A Solution of Benzaldehyde (0.01 M) in minimum quantity of DMF (5 ml) was 
added to the mixture of 2-(4-acetylphenylamino)pyridine-3-carbonitrile in 15ml DMF 
and 40% KOH was added to make mixture alkaline, the reaction mixture was then stirred 
for 24 hours at room temperature. The product was isolated by adding mixture in cold 
water and crystallized it from DMF. Yield 77%, m.p. 254°C. (C21H15N3O; required: C 
77.52%, H 4.65%, N 12.91%; found: C 77.39%, H 4.53%, N 12.86%). 
 
 
[B] Synthesis of 2-(4-(4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenylamino)pyridine-
3-carbonitrile. 
 A mixture of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile (0.01 
M) and hydrazine hydrate (0.05 M) in 25 ml Ethanol was refluxed for 10 hrs. The 
solution was poured into crushed ice and neutralize with dilute HCl solution. Product was 
isolated and crystallized from ethanol. Yield 65%, m.p. 1870C. 
 
Similarly other 2-(4-(4,5-dihydro-5-Aryl-1H-pyrazol-3-yl)phenylamino)pyridine-
3-carbonitrile were prepared, The physical data are recorded in the Table no-3. 
 
[C] Biological evaluation of 2-(4-(4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile.    
 
All the products have been evaluated for Antimicrobial activity as describe in 
part-I. The results of the solutions are recorded in Table No. 4. 
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Table No. 3. Physical Data Table of 2-(4-(4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
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Table No. 4. Biological evalution of 2-(4-(4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
Compounds R= Aryl Antibacterial Activity Antifungal Activity 
  
B. 
subtilis 
s. 
aureus 
P. 
aeruginosa 
E. 
coli 
A. 
niger 
C. 
albicans 
2a 3-NO2-C6H4- 
16 9 11 15 13 9 
2b 4-Cl-C6H4- 
8 13 18 11 17 13 
2c C4H3O- 15 8 9 12 9 15 
2d C6H5- 11 5 6 8 10 9 
2e 
N,N-
(CH3)2-
C6H4- 
13 16 11 15 14 18 
2f 4-OCH3-C6H4- 
17 19 13 14 17 12 
2g 2-OH- C6H4- 
15 17 17 13 12 13 
2h 2-Cl- C6H4- 
15 8 11 12 10 17 
2i 
4-OCH3-
2-OH-
C6H4- 
10 13 6 9 16 14 
2j 4-OH- C6H4- 
11 8 13 11 12 9 
2k 
3,4-
(OCH3)2-
C6H4- 
17 16 12 7 9 7 
2l 2-OH-C10H6 
8 11 8 10 5 11 
2m C8H6N- 9 13 14 6 9 14 
2n C7H14- 11 9 11 15 14 14 
2o 
2,5-
(OCH3)2-
C6H4- 
18 12 5 14 17 7 
2p 3,5-Cl2-2-OH-C6H4- 
18 9 12 16 13 18 
Sparfloxacin  25 24 25 22 - - 
Benzy 
penicillin  17 18 16 16 - - 
Ampicillin  19 23 20 20 - - 
Fluconazole  - - - - 22 20 
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ANTIBACTERIAL ACTIVITY:  
 
From screening results, substituted pyrazoline 2p (R = -3,5-Cl2-2-OH-C6H4-) and 
2o (R= 2,5-(OCH3)2-C6H4-) possesses very good activity against B. subtilis compared 
with Benzyl penicillin while 2b (R = 4-Cl-C6H4-) against P. aeruginosa, The remaining 
pyrazoline derivatives possess moderate to poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY:  
 
Antifungal screening data showed that substituted pyrazoline 2e (R = N,N-
(CH3)2-C6H4-) and 2p (R= 3,5-Cl2-2-OH-C6H4-) against C.albicans, While 2b (R= 4-Cl-
C6H4-) and 2o (R = 2,5-(OCH3)2-C6H4-) against A.niger, show highly promising activity 
compare with standard drug. While remaining compounds exhibited moderate to poor 
activity against both bacterial species. 
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SECTION-II 
Conventional and Microwave assisted Synthesis, biological evaluation of 2-(4-(1-
acetyl-4,5-dihydro-5-Aryl-1H-pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
Looking to the interesting properties of pyrazolines, with an intension to 
synthesizing better therapeutic agents, pyrazoline derivatives of Type-III has been 
synthesized.  
The constitution of the synthesized products have been characterized by using elemental 
analysis, Infrared and 1H-nuclear magnetic resonance spectroscopy and further supported 
by mass spectroscopy. 
All the compounds have been evaluated for their in vitro biological assay 
like antibacterial activity towards gram positive and gram negative bacterial 
strains and antifungal activity towards A.niger and C.Albicans. The biological 
activities of synthesized compounds were compared with standard drugs. 
N
CN
N
H
O
R
R= Aryl
N
CN
N
H
N
R
2-(4-((3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile
N
COCH3
2-(4-((3-arylacryloyl)phenylamino)pyridine-3-carbonitrile
AcOH, NH2NH2
Type-III  
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IR Spectral Study Of 2-(4-(1-acetyl-4,5-dihydro-5-(3,4-dimethoxyphenyl)-1H-
pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type Vibration Mode Frequency cm-1 Reference 
Alkane -C-H str. (asym.) 
-C-H str. (sym.) 
-C-H def. (asym.) 
-C-H def. (sym.) 
2932 
2860 
1458 
1367 
38 
,, 
,, 
,, 
Aromatic -C=C str. 
-C-H 
1518 
839 
,, 
,, 
Pyrazoline -C=O str. 
-C=N str 
-C-N str. 
1664 
1606 
1182 
,, 
,, 
,, 
Amine -N-H str  3310 39 
Nitrile -C≡N 2210 ,, 
 
N N
H
CN
N N
OCH3
OCH3
COCH3
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1H NMR Spectral Study Of 2-(4-(1-acetyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signal No Signal Position 
δppm 
Relative No Of 
Protons 
Multiplicity Inference 
1 2.1 3H Singlet -COCH3 (g) 
2 3.3-3.5 2H Double doublet -CH (a, b) 
3 5.6 1H Doublet -CH (c) 
4 6.8 2H Double 
Doublet 
-CH (i, i’) 
5 8.1 1H Doublet -CH (m) 
6 8.4 1H Singlet (broad) -NH (j) 
 
 
N
CN
N
H
N N
COCH3
a, b
c d
d'
e
e'
f
g
h
h'
i'
i
jk
l
m
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Mass Spectral Study Of 2-(4-(1-acetyl-4,5-dihydro-5-(3,4-dimethoxyphenyl)-1H-
pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
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N
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M
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EXPERIMENTAL 
 
Conventional and Microwave assisted Synthesis, biological evaluation of 2-(4-(1-
acetyl-4,5-dihydro-5-Aryl-1H-pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
 
[A] Synthesis of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile.   
A Solution of Benzaldehyde (0.01 M) in minimum quantity of DMF (5 ml) was 
added to the mixture of 2-(4-acetylphenylamino)pyridine-3-carbonitrile in 15ml DMF 
and 40% KOH was added to make mixture alkaline, the reaction mixture was then stirred 
for 24 hours at room temperature. The product was isolated by adding mixture in cold 
water and crystallized it from DMF. Yield 77%, m.p. 254°C. (C21H15N3O; required: C 
77.52%, H 4.65%, N 12.91%; found: C 77.39%, H 4.53%, N 12.86%). 
 
[B] Synthesis of 2-(4-(1-acetyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
A mixture of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile (0.01 
M) and hydrazine hydrate (0.05 M) in 15 ml glac acetic acid was refluxed for 8 hrs. The 
solution was poured into crushed ice and product was isolated and crystallized from 
ethanol. Yield 70%, m.p. 2100C. 
 
Similarly other 2-(4-(1-acetyl-4,5-dihydro-5-pheyl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile were prepared, The physical data are recorded in 
the Table No. 5. 
 
[C] Biological evalution of 2-(4-(1-acetyl-4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
All the products have been evaluated for Antimicrobial activity as describe in 
Part-I, The zone of inhibition of test solutions are recorded in Table No. 6. 
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Table No. 5 Past Physical Data of 2-(4-(1-acetyl-4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
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Table No. 6 Biological activity of 2-(4-(1-acetyl-4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
Compounds R= Aryl Antibacterial Activity Antifungal Activity 
    B. subtilis 
s. 
aureus 
P. 
aeruginosa E. coli 
A. 
niger 
C. 
albicans 
3a 3-NO2-C6H4- 12 15 20 14 14 18 
3b 4-Cl-C6H4- 16 17 18 19 11 19 
3c C4H3O- 13 11 10 13 10 7 
3d C6H5- 9 5 8 6 9 5 
3e N,N-(CH3)2-C6H4- 
15 10 16 10 15 11 
3f 4-OCH3-C6H4- 17 15 11 18 12 7 
3g 2-OH- C6H4- 15 11 18 19 9 13 
3h 2-Cl- C6H4- 11 18 10 12 5 11 
3i 4-OCH3-2-OH-C6H4- 
12 16 11 13 16 13 
3j 4-OH- C6H4- 13 9 11 16 13 11 
3k 3,4-(OCH3)2-C6H4- 
18 15 19 17 18 12 
3l 2-OH-C10H6 11 16 10 8 11 16 
3m C8H6N- 9 11 10 13 9 5 
3n C7H14- 12 9 12 11 6 10 
3o 2,5-(OCH3)2-C6H4- 
17 11 16 18 15 11 
3p 3,5-Cl2-2-OH-C6H4- 
21 17 17 18 18 13 
Sparfloxacin   25 24 25 22 - - 
Benzy 
penicillin   17 18 16 16 - - 
Ampicillin   19 23 20 20 - - 
Fluconazole   - - - - 22 20 
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ANTIBACTERIAL ACTIVITY:  
 
From screening results, substituted acetyl pyrazoline 3p (R = -3,5-Cl2-2-OH-
C6H4-) and 3k (R= 3,4-(OCH3)2-C6H4-) possesses very good activity against B. subtilis 
compared with Benzyl penicillin while 3a (R = 3-NO2-C6H4-) and 3k (R = 3,4-(OCH3)2-
C6H4-) against P. aeruginosa, 3b (R= 4-Cl-C6H4-), 3g (R= 2-OH- C6H4-) and 3p (R= -
3,5-Cl2-2-OH-C6H4-) possesses good activity against E.coli. The remaining acetyl 
pyrazoline derivatives possess modrate to poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY:  
 
Antifungal screening data showed that substituted acetyl pyrazoline 3b (R = 4-Cl-
C6H4-) against C.albicans, While 3k (R= 3,4-(OCH3)2-C6H4-) and 3p (R = 3,5-Cl2-2-OH-
C6H4-) against A.niger, show highly promising activity compare with standard drug. 
While remaining compounds exhibited moderate to poor activity against both bacterial 
species. 
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SECTION-III 
Conventional and Microwave assisted Synthesis, biological evaluation of 2-(4-(1-
phenyl-4,5-dihydro-5-Aryl-1-phenylpyrazol-3-yl)phenylamino)pyridine-3-
carbonitrile. 
With a view of getting better therapeutic agents and considering the association of 
various biological activities the preparation of pyrazolines of type-IV have been under 
taken. The constitution of the synthesized products have been characterized by using 
elemental analysis, Infrared, 1H-NMR and further supported by mass spectroscopy. 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards gram positive and gram negative bacterial strains and 
antifungal activity towards A.niger and C.Albicans. The biological activities of 
synthesized compounds were compared with standard 
drugs.
N
CN
N
H
O
R
R= Aryl
N
CN
N
H
N
R
N
Ph
2-(4-((3-arylacryloyl)phenylamino)pyridine-3-carbonitrile
Type-IV
2-(4-(1-phenyl-4,5-dihydro-5-Aryl-1-phenylpyrazol-3-yl)phenylamino)pyridine-3-carbonitrile
PhNHNH2
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IR spectral Study Of 2-(4-(5-(3,5-dichloro-2-hydroxyphenyl)-4,5-dihydro-1-phenyl-
1H-pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type Vibration Mode Frequency cm-1 Reference 
Alkane C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2907 
2848 
1429 
1340 
38 
,, 
,, 
,, 
Aromatic C-H str. 
C=C str. 
-C-Cl str 
3103 
1462 
752 
,, 
,, 
,, 
Pyrazoline C=N str. 
N-Ph 
1585 
1508 
,, 
Amine -N-H str  3331 39 
Nitrile -C≡N 2218 ,, 
 
N
CN
N
H
N OH
Cl
Cl
N
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1H NMR Spectral Study Of 2-(4-(4,5-dihydro-5-(4-methoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signal No Signal Position 
δppm 
Relative No 
Of Protons 
Multiplicity Inference 
1 2.6 1H Double Doublet -CHa 
2 2.4 1H Double Doublet -CHb 
3 3.3 3H Singlet -CH3 (m) 
4 5.3 1H double doublet -CH (x) 
5 6.4 2H Doublet -CH (h,h’) 
6 6.5 2H Doublet -CH (b,b’) 
7 7.7 2H Doublet -CH (g,g’) 
8 8.2 1H Singlet (broad) -NH 
N N
H
CN
N N
OCH3
x
Ha, Hb
a
a'
b
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Mass Spectral Study Of 2-(4-(5-(3,5-dichloro-2-hydroxyphenyl)-4,5-dihydro-1-
phenyl-1H-pyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
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EXPERIMENTAL 
[A] Synthesis of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile.   
A Solution of Benzaldehyde (0.01 M) in minimum quantity of DMF (5 ml) was 
added to the mixture of 2-(4-acetylphenylamino)pyridine-3-carbonitrile in 15ml DMF 
and 40% KOH was added to make mixture alkaline, the reaction mixture was then stirred 
for 24 hours at room temperature. The product was isolated by adding mixture in cold 
water and crystallized it from DMF. Yield 77%, m.p. 254°C. (C21H15N3O; required: C 
77.52%, H 4.65%, N 12.91%; found: C 77.39%, H 4.53%, N 12.86%). 
 
[B] Synthesis of 2-(4-(1-phenyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
A mixture of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile (0.01 
M) and Phenyl hydrazine (0.01 M) in 25 ml Ethanol was refluxed for 10 hrs. The solution 
was poured into crushed ice and neutralize with dilute HCl solution. Product was isolated 
and crystallized from ethanol. Yield 70%, m.p. 2540C. 
 
Similarly other 2-(4-(1-phenyl-4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile were prepared, The physical data are recorded in 
the Table No-7. 
 
[C] Biological evalution of 2-(4-(1-phenyl-4,5-dihydro-5-Aryl-1H-pyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 All the products have been evaluated for Antimicrobial activity as describe in 
Part-I. The zones of inhibition of test solutions are recorded in Table No. 8. 
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Table No. 7 Physical Data of 2-(4-(1-phenyl-4,5-dihydro-5-Aryl-1-phenylpyrazol-3-
yl)phenylamino)pyridine-3-carbonitrile. 
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Table No. 8 Biological Activity of 2-(4-(1-phenyl-4,5-dihydro-5-Aryl-1-
phenylpyrazol-3-yl)phenylamino)pyridine-3-carbonitrile. 
 
Compounds R= Aryl Antibacterial Activity Antifungal Activity 
    B. subtilis 
s. 
aureus 
P. 
aeruginosa 
E. 
coli 
A. 
niger 
C. 
albicans 
4a 3-NO2-C6H4- 17 12 16 13 12 9 
4b 4-Cl-C6H4- 19 15 11 18 11 15 
4c C4H3O- 12 15 11 12 6 9 
4d C6H5- 5 8 11 9 8 5 
4e N,N-(CH3)2-C6H4- 
15 11 17 12 15 11 
4f 4-OCH3-C6H4- 
17 13 12 17 10 14 
4g 2-OH- C6H4- 19 18 11 18 16 12 
4h 2-Cl- C6H4- 12 17 11 12 17 11 
4i 4-OCH3-2-OH-C6H4- 
11 14 9 10 10 16 
4j 4-OH- C6H4- 8 15 11 9 10 17 
4k 3,4-(OCH3)2-C6H4- 
19 11 10 13 8 11 
4l 2-OH-C10H6 7 14 9 11 9 5 
4m C8H6N- 6 12 7 12 12 6 
4n C7H14- 12 6 16 10 10 13 
4o 2,5-(OCH3)2-C6H4- 
12 15 11 10 12 10 
4p 3,5-Cl2-2-OH-C6H4- 
16 12 18 19 9 16 
Sparfloxacin   25 24 25 22 - - 
Benzyl 
penicillin   17 18 16 16 - - 
Ampicillin   19 23 20 20 - - 
Fluconazole   - - - - 22 20 
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ANTIBACTERIAL ACTIVITY:  
 
From screening results, substituted phenyl pyrazoline 4b (R = -4-Cl-C6H4-), 4g 
(R= 2-OH- C6H4-) and 4k (R= 3,4-(OCH3)2-C6H4-) possesses very good activity against 
B. subtilis compared with Benzyl penicillin while 4e (R = N,N-(CH3)2-C6H4-) and 4p (R 
= 3,5-Cl2-2-OH-C6H4-) against P. aeruginosa, 4b (R= 4-Cl-C6H4-), 4g (R= 2-OH- C6H4-) 
and 4p (R= 3,5-Cl2-2-OH-C6H4-) possesses very good activity against E.coli. The 
remaining phenyl pyrazoline derivatives possess moderate to poor activity against all four 
bacterial species.  
 
ANTIFUNGAL ACTIVITY:  
 
Antifungal screening data showed that substituted phenyl pyrazoline 4j (R = -4-
OH- C6H4-) against C.albicans and 4h (R = -2-Cl- C6H4-) against A.niger, show highly 
promising activity compare with standard drug. While remaining compounds exhibited 
moderate to poor activity against both bacterial species. 
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Part-III 
Studies On 
Pyrimidines derivatives 
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INTRODUCTION  
Heterocycles are abundant in nature and are of great significance to life because 
their structural subunits exist in many natural products such as vitamins, hormones, 
antibiotics etc. Hence, they have attracted considerable attention in the design of 
biologically active molecules. Oxopyrimidines & Thiopyrimidines and its derivatives 
represent one of the most active classes of compounds possessing a wide spectrum of 
biological activities. Pyrimidine derivatives which occurs in natural products like nucleic 
acid, vitamin-B and having remarkable pharmaceutical importance because of their broad 
spectrum of biological activities. Several analogs of nucleic acids like fluorouracil which 
has been used in cancer treatment. Pyrimidines are among those molecules that make life 
possible as being some of the building blocks of DNA and RNA.  
Pyrimidine is considered to be a resonance hybrid of the charged and uncharged 
cannonical structures, its resonance energy has been found to be less than benzene or 
pyridine. The naturally occuring pyrimidine derivatives was first isolated by Gabrial and 
Colman in 1870, and its structure was confirmed in 1953 as 5-β-D-gluco-pyranoside of 
divicine.  
Some oxo pyrimidines of physiologically as well as therapeutically importance are as 
under: e.g., Blasticidin, Zidovudine. 
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SYNTHETIC ASPECT  
Different methods for the synthesis of pyrimidinones have been cited in the 
literature
 [1]
.  
An efficient and robust solid-phase synthesis of 6-substituted-2,5,6,8-tetrahydro-3H-
imidazo[1,2-a]pyrimidin-7-one (II), 3-substituted-1,3,4,6,7,8-exahydropyrimido[1,2-
a]pyrimidin-2-ones (III) using Baylis Hillman reagent
[2]
. 
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Oliver Kappe et al.
[3] 
have synthesized dihydropyrimidine-5-carboxylicacid (IV) in two 
steps by multicomponent condensation of benzyl or allyl β-ketoesters with aldehyde and 
urea, followed by suitable benzyl or allyl deprotection strategies. 
 
The condensation of the azaenolates derived from readily available ketimines with 
fluorinated nitrile offers an efficient and straightforward entry to new fluorinated 1,3-
vinylogous amides. These versatile compounds in turn react with triphosgene to yield 
new fluorinated pyrimidin-2(1H)-ones (V) in high yield
[4]
. 
 
 
 
Fikret karci et al.
[5] 
have synthesized 4-amino-1H-benzo[4,5]imidazo[1,2-a] 
pyrimidin-2-one by the reaction of 2-aminobenzimidazole with ethylcyanoacetate.  
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There are many other methods of pyrimidine ring synthesis which are of more limited 
scope. The reaction of 1,3-dicarbonyl compound or an equivalent reagent with 
formamide provides a route of several pyrimidine which are unsubstituted at the 2-
position. 
 
Biginelli
[6] 
investigated that condensation of aromatic aldehyde with β-ketoester and urea 
yield the pyrimidine derivatives (VI). 
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REACTION MECHANISM  
The reaction mechanism for the formation of pyrimidine derivatives described as under. 
 
THERAPEUTIC IMPORTANCE  
It is revealed from the literature survey that pyrimidine derivatives have been 
found to possessing biological activities mentioned as under.  
1. Anti HIV
[7,8]
 
2. Antiviral
[9]
 
3. Antimicrobial
[10]
 
4. Herbicidal
[11-17]
 
5. Antagonists
[18-22] 
 
6. Antitumor
[23]
 
7. Antiinflammatory and anticonvulsant
[24,25]
 
8. Carcinostatic
[26]
 
9. Antimalarial
[27]
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10. Antithyroid
[28] 
 
Sanjay Batra et al.
[29] 
have synthesized several 1-(2-cyano-3-aryl-allyl)-3-urea by the 
reaction between allylamines generated from Baylis-Hilman acetates and substituted 
isocyanates and isothiocyanate. Further, their cyclization in the presence of a base led to 
the formation of 5-arylmethyl-4-imino-3-aryl-3,4-dihydro-1H-pyrimidin-2-ones (VII) and 
were tested for their antibacterial activity. 
 
2-(Arylcarbonylmethyl)thio-6-alpha-naphthylmethyld derivatives of dihydro 
alkoxybenzyloxopyrimidines
[30] 
(DABO) were newly found to exhibit activity against 
both HIV-1 and HIV-2. These compounds were evaluated for their in vitro anti-HIV 
activity in MT-4 cells. The IC(50) values for anti-HIV-1 and HIV-2 were found 
moderately active.  
(±)-1-(anti-3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-
dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one (RO4383596) is a potent and selective 
inhibitor of the pro-angiogenic receptor tyrosine kinases KDR, FGFR, and PDGFR
[31]
. 
This agent has an excellent pharmacokinetic profile and is highly efficacious in rodent 
models of angiogenesis upon oral administration.  
Relationship between the topological indices and anti-HIV activity of 
dihydro(alkylthio)(napthylmethyl) oxopyrimidines (5-DABO) has been investigated by 
Lather V. and Madau A. K.
[32] 
The use of models based upon these topological indices 
resulted in prediction of anti-HIV activity with an accuracy ranging from 86% to 89%. 
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Herve Ganeste and co-workers
[33] 
synthesized substituted 1H-pyrimidin-2-one (VIII) with 
selective dopamine D3-receptor antagonists activity. 
 
2-Alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-(3H)  
-ones (F (2)-NH-DABOs) 4,5 belonging to dihydro-alkoxy-benzyl-oxopyrimidine 
(DABO)
[34] 
and bearing different alkyl and arylamino side chains at the C (2)-position of 
the pyrimidine ring were designed as active against wild type (wt) Human 
Immunodeficiency virus type 1 (HIV-1) and some relevant HIV-1 mutants. 
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Thirty six allyl substituted oxopyrimidine analogues
[35] 
such as barbituric acid 
(BA), barbiturates, uracil, thymine, and related derivatives including 13 new compounds 
were synthesized and their pharmacologic effects ([hypnotic activity, anticonvulsant 
activity against pentylentetrazol (PTZ)-induced seizures, and LD(50)]) and interactions 
with the barbiturates were evaluated in mice and rats.  
Bruce M. A. and co-workers
[36] 
have prepared the dihydropyrimidinones (IX) as 
NPY antagonists. Sidler and Larsen
[37] 
have reported pyrimidinone derivatives (X), useful 
as an α-adrenergic receptor antagonists.  
Pyrimidinone derivatives
[38]
(XI) have been found to be calcium channel blocker. 
Barbuliene M. M. et al.
[4O] 
have synthesized pyrimidinones as antiinflammatory agent. 
 
Amuti Kofies et al.
[41] 
have suggested pyrimidinones (XII) and (XIII) as herbicidal and 
plant growth regulators. 
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Swaminathan R. et al.
[42] 
have synthesized P38 MAP Kinase inhibitors based on 3,4-
dihydropyrimido[4,5-d]pyrimidin-2-ones (XIV) . 
 
Cano Soldado P. et al.
[43] 
have described pyrimidine derivatives as nucleoside inhibitors 
of HIV-1. Gompel M. et al.
[44] 
have reported new family of protein kinase inhibitors 
isolated from the ascidian aplidium meridianum. Junmei Wang et al.
[45] 
have prepared 
hierarchical database screenings for HIV-1 Reverse Transcriptase (XV). 
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S. S. Sangapure
[46] 
have tested the antimicrobial activity of benzofuro[3,2-d]pyrimidine 
derivatives (IX). El Sayed
[47] 
have synthesized alkylated substituted mercapto pyrimidine 
derivatives (X) and studied their anticancer and antineoplastic activity. H. Y. Moustafa
[48] 
have reported some pyrimidine derivatives and studied their biological activities. 
 
Shimizu T. et al.
[49] 
have described N3-substituted uridine and related Pyrimidine 
nucleosides as antinociceptive effects in mice. Sanmartin C. et al.
[50] 
have prepared new 
symmetrical derivatives as cytotoxic agents and apoptosis inducers. Agarwal A. et al.
[51] 
have synthesized 2,4,6-trisubstituted pyrimidine derivatives as pregnancy 
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interceptiveagents. Shigeta S. et al.
[52] 
have been synthesized 5-alkyl-2-thiopyrimidine 
nucleoside analogues and examined for antiviral activities against Herps Simplex virus 
(HSV), Varicella-Zoster virus (SZV) and Human Cytomegalo virus (HCMV). 
Thus, diverse biological activities have been encountered in compounds containing 
oxopyrimidine ring system. To further assess the potential of such type of compounds, 
study of oxopyrimidines has been carried out. 
 
 
 
 
 
Section-I Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(1,2-dihydro-6-Aryl-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 
Section-II Conventional and Microwave assisted Synthesis, biological 
evaluation of 2-(4-(1,2-dihydro-2-oxo-6-Arylpyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
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Section-I 
 
Conventional and Microwave assisted Synthesis, biological evaluation of 2-(4-(1,2-
dihydro-6-Aryl-2-thioxopyrimidin-4-yl)phenylamino)pyridine-3-carbonitrile. 
 
Thioxopyrimidines represent one of the most active classes of compounds possessing a 
wide spectrum of biological activities, such as significant in vitro activity against viruses 
including polio viruses, diuretic, antitubercular spermidical etc. These valid observation 
led us to synthesize 2-(4-(1,2-dihydro-6-Aryl-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile of Type (V) by cyclocondensation of chalcones 
of Type (I) and Thiourea in presence of KOH as catalyst. 
 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 
1
H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy.  
 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger and C. Albican. The biological activities of 
synthesized compounds were compared with standard drugs.  
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Reaction Scheme 
 
N N
H
CN
R
O
KOH
EtOH
Thiourea
N N
H
CN
R
N NH
S
R= ArylType-V
 
 
 
 
 
 
 
 
 
 
 
Studies On Some Heterocyclic Compounds…… 
 
Page 103 
 
IR Spectral Study Of 2-(4-(6-(4-chlorophenyl)-1,2-dihydro-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type Vibration Mode Frequency cm-1 Reference 
Alkane C-H str. (asym.)  
C-H str. (sym.) 
C-H def. (asym.)  
C-H def. (sym.)  
2918 
2860 
1417 
1253 
49 
,, 
,, 
,, 
Aromatic C-H str.  
C=C  
3198 
1521 
,, 
,, 
Thiopyrimidine C=S str.  
N-H str.  
1589 
3302 
,, 
,, 
Halide C-Cl str. 771 50 
Nitrile -C≡N 2322 ,, 
 
N
CN
N
H
N NH
S
Cl
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1H NMR Spectral Study Of 2-(4-(1,2-dihydro-6-(3,4-dimethoxyphenyl)-2-
thioxopyrimidin-4-yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signal No. Signal Position 
δppm 
Relative No Of 
Protons 
Multiplicity Inference 
1 3.8 6H Singlet 
(overlapped) 
-CH3 (g, f)  
2 5.2 1H Singlet -CH (a) 
3 6.6 3H Double doublet -CH (i, i’, e) 
4 6.8 2H Singlet -CH (c, d) 
5 7.8 1H Singlet -NH (b) 
6 7.9 2H Double doublet -CH (h, h’) 
7 8.2 1H Singlet -NH (j) 
N
CN
N
H
N NH
S
OCH3
OCH3
a
b
c
d
e f
g
h
h'
i'
i
jk
l
m
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Mass Spectral Study Of 2-(4-(6-(4-chlorophenyl)-1,2-dihydro-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
NC NH
N
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EXPERIMENTAL 
 
[A] Synthesis of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile.   
A Solution of Benzaldehyde (0.01 M) in minimum quantity of DMF (5 ml) was 
added to the mixture of 2-(4-acetylphenylamino)pyridine-3-carbonitrile in 15ml DMF 
and 40% KOH was added to make mixture alkaline, the reaction mixture was then stirred 
for 24 hours at room temperature. The product was isolated by adding mixture in cold 
water and crystallized it from DMF. Yield 77%, m.p. 254°C. (C21H15N3O; required: C 
77.52%, H 4.65%, N 12.91%; found: C 77.39%, H 4.53%, N 12.86%). 
 
[B] Synthesis of 2-(4-(1,2-dihydro-6-phenyl-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
 
A mixture of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile (0.01 
mol) and Thiourea (0.01 mol) in ethanol (20 ml) was refluxed on water bath in presence 
of alcoholic KOH for 10 hrs. The excess solvent was distilled off and the residue was 
neutralized with 10% HCl, the separated solid was filtered out and crystallized from 
ethanol. Yield 70 %, m.p. 268OC.  
  
 Similarly, other 2-(4-(1,2-dihydro-6-Aryl-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile  were prepared. The physical data are recorded in 
Table No. 9. 
 
[C] Biological Evaluation Of 2-(4-(1,2-dihydro-6-Aryl-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
  
 Antimicrobial testing were carried out as described in Part-I. The zones of 
inhibition of test solutions are recorded in Table No. 10.  
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Table No. 9 Physical Data of 2-(4-(1,2-dihydro-6-Aryl-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
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Table No. 10 Biological Activity of 2-(4-(1,2-dihydro-6-Aryl-2-thioxopyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
 
Compounds R= Aryl Antibacterial Activity Antifungal Activity 
    B. subtilis 
s. 
aureus 
P. 
aeruginosa E. coli 
A. 
niger 
C. 
albicans 
5a 3-NO2-C6H4- 
19 14 16 12 19 14 
5b 4-Cl-C6H4- 16 14 12 19 17 19 
5c C4H3O- 10 8 12 9 12 15 
5d C6H5- 9 10 11 8 9 7 
5e 
N,N-
(CH3)2-
C6H4- 
13 15 11 10 12 8 
5f 4-OCH3-C6H4- 
18 16 12 16 11 14 
5g 2-OH- C6H4- 
20 17 16 19 6 9 
5h 2-Cl- C6H4- 
16 12 18 10 11 12 
5i 4-OCH3-2-OH-C6H4- 
13 11 15 9 16 12 
5j 4-OH- C6H4- 
9 10 13 10 19 11 
5k 
3,4-
(OCH3)2-
C6H4- 
19 15 18 12 16 20 
5l 2-OH-C10H6 
9 12 7 8 17 12 
5m C8H6N- 7 9 6 8 8 5 
5n C7H14- 11 9 10 7 9 12 
5o 
2,5-
(OCH3)2-
C6H4- 
12 15 12 10 14 17 
5p 3,5-Cl2-2-OH-C6H4- 
20 16 14 18 15 19 
Sparfloxacin   25 24 25 22 - - 
Benzy 
penicillin   17 18 16 16 - - 
Ampicillin   19 23 20 20 - - 
Fluconazole   - - - - 22 20 
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ANTIBACTERIAL ACTIVITY:  
 
From screening results, substituted acetyl Thiopyrimidine 5g (R = -2-OH- C6H4-) 
and 5p (R= 3,5-Cl2-2-OH-C6H4-) possesses very good activity against B. subtilis 
compared with Benzyl penicillin while 5b (R = 4-Cl-C6H4-) and 5g (R= -2-OH- C6H4-) 
against E.coli, The remaining Thiopyrimidine derivatives possess moderate to poor 
activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY:  
 
Antifungal screening data showed that substituted Thiopyrimidine 5b (R = 4-Cl-
C6H4-) and 5k (R= 3,4-(OCH3)2-C6H4-) against C.albicans, While 5a (R= 3-NO2-C6H4-) 
and 5j (R= 4-OH- C6H4-) against A.niger, show highly promising activity compare with 
standard drug. While remaining compounds exhibited moderate to poor activity against 
both bacterial species. 
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SECTION-II 
 
Conventional and Microwave assisted Synthesis, biological evaluation of 2-(4-(1,2-
dihydro-2-oxo-6-Arylpyrimidin-4-yl)phenylamino)pyridine-3-carbonitrile. 
 
In the past years considerable evidence has been accumulated to demonstrate the 
efficiency of pyrimidinones. 2-(4-(1,2-dihydro-2-oxo-6-Arylpyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile of Type (VI) have been prepared by the 
condensation of 2-(4-(3-arylacryloyl)phenylamino)pyridine-3-carbonitrile of Type (I) 
with urea in presence of basic catalyst as shown under. 
 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy.  
 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger and C. Albicans. The biological activities of 
synthesized compounds were compared with standard drugs. 
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REACTION SCHEME 
 
N N
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CN
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KOH
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N N
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IR Spectral Study Of 2-(4-(1,2,5,6-tetrahydro-6-(4-hydroxyphenyl)-2-
oxopyrimidin-4-yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type Vibration Mode Frequency cm-1 Reference 
Alkane C-H str. (asym.)  
C-H str. (sym.)  
C-H def. (asym.)  
C-H def. (sym.)  
2898 
2760 
1408 
1361 
49 
,, 
,, 
,, 
Aromatic C-H str.  
C=C 
3103 
1525 
,, 
,, 
Oxopyrimidine C=O str.  
C=N str.  
C–N str.  
N-H str.  
1658 
1588 
1172 
3337 
,, 
50 
,, 
,, 
Nitrile  -C≡N 2253 ,, 
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CN
N
H
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1H NMR Spectral Study Of 2-(4-(1,2-dihydro-6-(4-methoxyphenyl)-2-oxopyrimidin-
4-yl)phenylamino)pyridine-3-carbonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signal 
No 
Signal Position δppm Relative No Of 
Protons 
Multiplicity Inference 
1 3.3 3H Singlet -OCH3 (c) 
2 5.1 1H Singlet -Ar-H (a) 
3 6.8 2H  Double 
Doublet 
-CH (g,g’) 
4 7.0 1H Triplet -CH (j) 
5 8.3 2H Double 
Doublet 
-CH (i) 
6 8.4 1H Singlet (broad) -NH (h) 
7 8.8 1H Singlet -NH (b) 
 
N
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N
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Mass Spectral Study Of 2-(4-(1,2,5,6-tetrahydro-6-(4-hydroxyphenyl)-2-
oxopyrimidin-4-yl)phenylamino)pyridine-3-carbonitrile. 
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EXPERIMENTAL 
 
Conventional and Microwave assisted Synthesis, biological evaluation of 2-(4-(1,2-
dihydro-2-oxo-6-Arylpyrimidin-4-yl)phenylamino)pyridine-3-carbonitrile. 
 
[A] Synthesis of 2-(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile.   
A Solution of Benzaldehyde (0.01 M) in minimum quantity of DMF (5 ml) was 
added to the mixture of 2-(4-acetylphenylamino)pyridine-3-carbonitrile in 15ml DMF 
and 40% KOH was added to make mixture alkaline, the reaction mixture was then stirred 
for 24 hours at room temperature. The product was isolated by adding mixture in cold 
water and crystallized it from DMF. Yield 77%, m.p. 254°C. (C21H15N3O; required: C 
77.52%, H 4.65%, N 12.91%; found: C 77.39%, H 4.53%, N 12.86%). 
 
[B] Synthesis of 2-(4-(1,2-dihydro-2-oxo-6-phenylpyrimidin-4-yl)phenylamino) 
pyridine-3-carbonitrile. 
 
A mixture of -(4-(3-phenylacryloyl)phenylamino)pyridine-3-carbonitrile (0.01 mol) 
and urea (0.01 mol) in ethanol (20 ml) was refluxed on water bath in presence of 
alcoholic KOH for 12 hrs. The excess solvent was distilled off and the residue was 
neutralized with 10% HCl, the separated solid was filtered out and crystallized from 
methanol. Yield 71 %, m.p. 2190C.  
 
Similarly, other 2-(4-(1,2-dihydro-2-oxo-6-Arylpyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile were prepared. The physical data are recorded in 
Table no. 11. 
 
[C] Biological evaluation of 2-(4-(1,2-dihydro-2-oxo-6-Arylpyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile 
  
 Antimicrobial testing were carried out as described in Part-I. The zones of 
inhibition of test solutions are recorded in Table No. 12 
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Table No. 11 Physical Data of 2-(4-(1,2-dihydro-2-oxo-6-Arylpyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
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Table No. 12 Biological Activity Of 2-(4-(1,2-dihydro-2-oxo-6-Arylpyrimidin-4-
yl)phenylamino)pyridine-3-carbonitrile. 
Compounds R= Aryl Antibacterial Activity Antifungal Activity 
    B. subtilis s. aureus 
P. 
aeruginos
a 
E. coli A. niger 
C. 
albicans 
6a 3-NO2-C6H4- 
20 16 12 17 14 9 
6b 4-Cl-C6H4- 16 12 19 15 11 15 
6c C4H3O- 13 16 10 13 7 4 
6d C6H5- 8 10 9 5 9 10 
6e N,N-(CH3)2-C6H4- 
18 13 9 16 17 13 
6f 4-OCH3-C6H4- 
19 14 18 14 12 17 
6g 2-OH- C6H4- 
19 12 18 15 11 6 
6h 2-Cl- C6H4- 14 10 9 13 8 12 
6i 4-OCH3-2-OH-C6H4- 
15 12 17 10 10 12 
6j 4-OH- C6H4- 
12 9 16 12 17 10 
6k 
3,4-
(OCH3)2-
C6H4- 
20 12 17 13 12 10 
6l 2-OH-C10H6 11 9 13 6 10 5 
6m C8H6N- 9 6 12 10 11 7 
6n C7H14- 12 7 12 10 9 4 
6o 
2,5-
(OCH3)2-
C6H4- 
16 11 18 17 14 10 
6p 3,5-Cl2-2-OH-C6H4- 
20 17 18 14 11 17 
Sparfloxacin   25 24 25 22 - - 
Benzy 
penicillin   17 18 16 16 - - 
Ampicillin   19 23 20 20 - - 
Fluconazole   - - - - 22 20 
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ANTIBACTERIAL ACTIVITY:  
 
From screening results, substituted acetyl Oxopyrimidine 6a (R = -3-NO2-C6H4-), 
6p (R= 3,5-Cl2-2-OH-C6H4-) and 6k (R= 3,4-(OCH3)2-C6H4-) possesses very good 
activity against B. subtilis compared with Benzyl penicillin while 6b (R = 4-Cl-C6H4-) 
against P. aeruginosa, The remaining Oxopyrimidine derivatives possess moderate to 
poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY:  
 
Antifungal screening data showed that substituted Oxopyrimidine 6f (R = 4-
OCH3-C6H4-) and 6p (R= 3,5-Cl2-2-OH-C6H4-) against C.albicans, While 6e (R= N,N-
(CH3)2-C6H4-) and 6j (R = 4-OH- C6H4-) against A.niger, show highly promising activity 
compare with standard drug. While remaining compounds exhibited moderate to poor 
activity against both bacterial species. 
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Abstract: 
 
Keto group of cyano pyridine moiety have been treated with various aromatic 
aldehydes to give corresponding chalcones. The Chalcones have been reacted with urea 
and thiourea to get corresponding novel oxopyrimidines and thiopyrimidines, the 
structure of all newly synthesized compounds were confirmed by spectral analysis. The 
synthesized compounds were evaluated for their antimicrobial activity. All the 
synthesized pyrimidine compounds have show good to moderate antimicrobial activity. 
 
 
